- Report
- May 2023
- 169 Pages
Global
From €2260EUR$2,350USD£1,938GBP
- Report
- January 2024
- 200 Pages
Global
From €3990EUR$4,150USD£3,423GBP
- Report
- February 2021
- 360 Pages
United States
From €2308EUR$2,400USD£1,980GBP
- Report
- February 2019
- 105 Pages
Global
From €1240EUR$1,290USD£1,064GBP
- Drug Pipelines
- June 2019
- 579 Pages
Global
€21154EUR$22,000USD£18,147GBP
- Report
- June 2019
- 15 Pages
Global
€9615EUR$10,000USD£8,249GBP
- Report
- June 2019
- 15 Pages
Global
€9615EUR$10,000USD£8,249GBP
- Report
- April 2021
- 64 Pages
Global
€21154EUR$22,000USD£18,147GBP
- Report
- January 2019
- 717 Pages
Global
From €21154EUR$22,000USD£18,147GBP
- Report
- February 2024
- 87 Pages
Global
From €3500EUR$3,899USD£3,108GBP
- Report
- November 2023
- 35 Pages
Global
From €5596EUR$5,820USD£4,801GBP
The Odefsey market is a subset of the HIV/AIDS drug market, focusing on the development and distribution of antiretroviral drugs. These drugs are used to treat HIV infection and reduce the risk of HIV transmission. Odefsey is a combination of two drugs, emtricitabine and rilpivirine, which are used in combination with other antiretroviral drugs to treat HIV infection. Odefsey is a once-daily, single-tablet regimen that is designed to be taken with or without food. It is approved for use in adults and adolescents aged 12 years and older.
The Odefsey market is highly competitive, with several major pharmaceutical companies competing for market share. These companies include Gilead Sciences, Janssen Pharmaceuticals, Merck & Co., and ViiV Healthcare. Each of these companies has developed and marketed their own version of Odefsey, and they are continually striving to improve the efficacy and safety of their products. Show Less Read more